Research programme: CNS cancer therapeutics - Angiochem/Geron Corporation
Latest Information Update: 07 Dec 2012
At a glance
- Originator AngioChem; Geron Corporation
- Class Drug conjugates; Oligonucleotides; Peptides
- Mechanism of Action Telomerase inhibitors; Tubulin polymerisation promoters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain cancer